EC95 of Remifentanil for Preventing Cough
- Registration Number
- NCT02973724
- Lead Sponsor
- Ajou University School of Medicine
- Brief Summary
The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.
- Detailed Description
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- ASA I-II patients undergoing general anesthesia for laryngomicrosurgery
Exclusion Criteria
- Anticipated difficult airway
- COPD, Asthma
- Recent URI (< 2 weeks)
- Severe cardiac, hepatic renal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Remifentanil Propofol anesthesia Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods. Remifentanil Remifentanil Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
- Primary Outcome Measures
Name Time Method Number of cough from end of surgery to 5 min after tracheal extubation Number of cough or a strong and sudden contraction of the abdomen during periextubation periods
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ajou University Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of